Skip to main navigation
Go to  Indivior Pharmaceuticals, Inc. corporate website
  • Overview
  • News & Events
    • Results, Reports & Presentations
    • News Releases
    • Events
  • Stock
    • Stock Quote & Chart
    • Historical Price Lookup
    • Analyst Coverage
  • Shareholder Info
    • Redomiciliation
    • London Delisting
    • Managing Your Shares
    • Shareholder Meetings
    • Investor FAQs
  • Governance
    • Governance Overview
    • Committees
    • Tax Strategy
  • Financials
    • SEC Filings
    • RNS Filings
  • Resources
    • Contact Us
    • Alerts Service
News & Events
  • Results, Reports & Presentations
  • News Releases
  • Events

News Releases

  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
December 8, 2021
Indivior to Present New Data on Buprenorphine Extended-Release at the 2021 Joint International Congress with ALBATROS and the World Association on Dual Disorder (WADD)
November 8, 2021
Indivior Presents Modelling Data on Interaction Between Buprenorphine and Fentanyl in Opioid-Naïve and Opioid-Tolerant Subjects at the 2021 American Conference of Pharmacometrics
November 2, 2021
Indivior to Participate in Upcoming November 2021 Healthcare Investor Conferences
November 1, 2021
Indivior Presents Study at the 2021 National Commission on Correctional Health Care Conference on Factors Impacting Medications for Opioid Use Disorder Treatment Approaches in Criminal Justice-Involved Populations
October 28, 2021
Indivior Announces Q3 and Nine Months 2021 Results; Raises FY 2021 Guidance
October 27, 2021
Indivior Applauds New York State Legislation to Combat Opioid Crisis for People Suffering from Substance Use Disorder within the New York State and Local Correctional institutions
October 21, 2021
Indivior to Present New Data on Opioid Use Disorder at CSAM-SMCA 2021 Scientific Conference
September 14, 2021
Indivior to Participate in Upcoming Healthcare Events During National Recovery Month
September 9, 2021
Indivior to Participate in Upcoming Investor Conferences
July 27, 2021
Indivior Announces H1 and Q2 2021 Financial Results
  • Current page 1
  • Page 2
  • Page 3
  • Next page ›
  • Last page »
Displaying 1 - 10 of 26

Investor Contact

person Jason Thompson
Work Vice President, Investor Relations
drafts InvestorRelations@indivior.com

Subscribe to our Email Alerts

Indivior Pharmaceuticals, Inc. Logo
Indivior Pharmaceuticals, Inc. Logo
© 2026 Indivior Pharmaceuticals, Inc.
This site is intended for US audiences
INDIVIOR is a registered trademark of Indivior UK Limited
Explore
  • Our Company
  • Our Science
  • Our Products
  • Our Impact
Useful Links
  • Terms of Use
  • Privacy Policy
  • Accessibility
  • Cookie Policy
  • Product Query or Adverse Event
Get in touch
  • Contact Us
  • LinkedIn
  • X
  • Our Social Media Community Guidelines
Search Investors